Fig. 2
Transcriptome analyses in PARP inhibitor-treated HeLa cells. (A) Experimental scheme for transcriptome analyses. (B) Heatmap of clustered DEGs in DMSO- and olaparib-treated HeLa cells. Red and blue indicate upregulated and downregulated gene sets, respectively. (C) Volcano plot of DEGs in olaparib-treated HeLa cells. Red and blue indicate significantly upregulated and downregulated gene sets in olaparib-treated cells compared with DMSO-treated cells. The representative genes in cytokine–cytokine receptor interaction pathways are highlighted. (D) Top ten enriched gene sets and their normalized enrichment scores (NES) in olaparib-treated HeLa cells. Yellow indicates inflammatory cytokine-related pathways. (E) Dot plots of the NES of the enriched hallmark pathways in olaparib-treated HeLa cells. The dot color and size indicate adjusted p-values and counts, respectively. Inflammatory-associated hallmarks are highlighted. (F) GSEAs of representative inflammation-related terms. GSEAs were performed in comparison between olaparib and DMSO treatments. (G) Dose-dependent effect of olaparib on cell viability (black line) and IRF reporter activity (red bars). A549-reporter cells were treated with olaparib at the indicated concentrations for 120 h. Data are shown as means ± SD (n = 6).
